Pathophysiology and treatment of atherosclerosis Current view and future perspective on lipoprotein modification treatment

• Published in: Netherlands heart journal Vol. 25; no. 4; pp. 231 - 242
• Main Authors: Bergheanu, S. C., Bodde, M. C., Jukema, J. W.
• Format: Journal Article
• Language: English
• Published: Houten Bohn Stafleu van Loghum 01.04.2017
• Subjects: Cardiology; Medical Education; Medicine; Medicine & Public Health; Review; Review Article; Low-density lipoprotein; Cardiovascular disease; Hypercholesterolaemia; Proprotein convertase subtilisin/kexin type-9; Statins; Atherosclerosis
• ISSN: 1568-5888; 1876-6250
• DOI: 10.1007/s12471-017-0959-2

Recent years have brought a significant amount of new results in the field of atherosclerosis. A better understanding of the role of different lipoprotein particles in the formation of atherosclerotic plaques is now possible. Recent cardiovascular clinical trials have also shed more light upon the efficacy and safety of novel compounds targeting the main pathways of atherosclerosis and its cardiovascular complications. In this review, we first provide a background consisting of the current understanding of the pathophysiology and treatment of atherosclerotic disease, followed by our future perspectives on several novel classes of drugs that target atherosclerosis. The focus of this update is on the pathophysiology and medical interventions of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and lipoprotein(a) (Lp(a)).